- Home /
- About us /
- Our management /
- Board of Directors /
The role of the Board of Directors is to determine long-term strategy; to monitor the achievement of business objectives; to ensure the Group has adequate available resources; to promote good corporate governance; and to ensure that the Group meets its responsibilities to shareholders, employees, customers and other stakeholders.
Samih Darwazah
Non-Executive Chairman
Samih Darwazah, a qualified pharmacist, worked for Eli Lilly from 1964 to 1976, before establishing Hikma Pharmaceuticals Ltd. in 1978. Between 1995 and 1996 he served as Minister of Energy and Mineral Resources in Jordan. He also founded the Jordan Trade Association and was a member of the Advisory Economic Council to His Majesty the King of Jordan. Samih holds a masters degree from the St. Louis College of Pharmacy, Missouri.
Said Darwazah
Chief Executive Officer
Said Darwazah served as Chairman and CEO of Hikma Investment Company, then the holding company for the Hikma Group, from 1994 until 2003. From 2003 until 2006 he held the position of Minister of Health in the Hashemite Kingdom of Jordan. Said is currently on the Board of Directors of the Central Bank of Jordan and the King Hussein Cancer Institute. He has a degree in Industrial Engineering from Purdue University in the United States and an M.B.A. from INSEAD, France.
Mazen Darwazah
Vice-Chairman
Mazen Darwazah joined Hikma in 1985 as a medical representative and has held several positions, including Chairman and CEO of Hikma Pharmaceuticals Limited - Jordan, Chairman of Trust Pharma Limited and Pharma Ixir Co. Ltd. He is a member of the Nomination Committee. He is a director of Jordan International Insurance Company, Capital Bank of Jordan and of several other organisations. From 2001 to 2003 he was the president of the Jordanian Association of Manufacturers of Pharmaceuticals and Medical Appliances, and has served as a member of the Jordanian Higher Education Counsel since 2003. Mazen holds a degree from Beirut University, Lebanon.
Ali Al-Husry
Non-Executive Director
Ali Al-Husry has been a director of Hikma Pharma Limited and other companies within the Hikma group since 1991. He is also serving as Chairman and Chief Executive Officer of Capital Bank of Jordan. He is also a director of The Association of Banks in Jordan, the Jordanian Insurance Commission and several other organizations. He brings great financial experience to the Board as well as an in-depth knowledge of the MENA region. Ali has a degree in mechanical engineering from the University of Southern California and an M.B.A. from INSEAD, France.
Sir David Rowe-Ham
Senior Independent Non-Executive Director
Sir David Rowe-Ham was appointed to the Board in October 2005 and currently holds the position of Chairman of the Nomination Committee. He is also a member of the Audit Committee and the Remuneration Committee. Sir David brings to Hikma a wide experience in financial matters, corporate governance, public affairs and the development of listed companies. He is also Chairman of Arden Partners plc, Olayan Europe Ltd. and Peninsular South Asia Investment Co. Ltd..
Michael Ashton
Independent Non-Executive Director
Michael Ashton was appointed to the Board in October 2005 and currently holds the position of Chairman of the Remuneration Committee. He is also a member of the Audit Committee and the Nomination Committee. Michael is the Group President and Chief Executive Officer of LMA International and also serves on the boards of Transition Therapeutics and Proximagen.
Breffni Byrne
Independent Non-Executive Director
Breffni Byrne was appointed to the Board in October 2005 and currently holds the position of Chairman of the Audit Committee. He is also a member of the Remuneration Committee. As a chartered accountant with over 30 years of experience in public practice, he has extensive experience in financial reporting, corporate governance and general financial and commercial matters. Breffni is Chairman of NCB Stockbrokers and a director of Irish Life and Permanent plc, Coillte Teoranta (the Irish state forestry company), Adsteam Europe Limited and other companies.
Ronald Goode
Independent Non-Executive Director
Ronald Goode was appointed to the Board in December 2006. He is a member of both the Audit and Remuneration Committees. Ron has spent over 30 years in the international pharmaceutical industry, including having held senior positions with Pfizer and Searle. He is the Chairman of The Goode Group, advisers to the pharmaceutical industry, and is a director of Mercy Ships International and a trustee of Thunderbird. He is also a director of Genitope Corporation, a NASDAQ-listed company. He was formerly President and Chief Executive Officer of Unimed Pharmaceuticals, Inc. and eXegenics Inc., and a director of serveral other companies, including Hokuriku Seiyaku and Vitro Diagnostics.
